NP方案化疗同步放疗并序贯过继免疫细胞治疗非小细胞肺癌的临床研究  

Effection of NP concurrent chemotherapy radiotherapy and sequential adoptive immunity cell for locally advanced non-small cell lung cancer

作　　者：徐永茂[1] 徐冬云[1] 张南征[1] 陈复兴[2] 张国龙[3] 刘军权[2] 李春艳[3] 

机构地区：[1]解放军第九七医院肿瘤科,江苏徐州221004 [2]解放军第九七医院实验科,江苏徐州221004 [3]解放军第九七医院放疗科,江苏徐州221004

出　　处：《中华肿瘤防治杂志》2011年第13期1032-1035,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:对比采用化疗、放射治疗、细胞因子诱导的杀伤(CIK)细胞+树突状细胞(DC)过继免疫综合治疗局部晚期非小细胞肺癌与单纯同步放化疗的临床疗效。方法:85例局部晚期非小细胞肺癌患者随机分成研究组45例(化放疗+过继免疫)与对照组40例(化放疗),研究组采用NP方案化疗同步放射治疗并序贯CIK细胞与DC综合治疗,对照组采用NP方案化疗同步放射治疗,观察疗效、毒副反应、患者生活存质量及免疫功能。结果:研究组近期有效率80.0%(36/45)明显高于对照组57.5%(23/40,P<0.05),生存质量及免疫功能明显高于对照组,两组毒副反应差异无统计学意义,P>0.05。研究组2年生存率64.4%(29/45)与1年无进展生存率75.6%(34/56)显著高于对照组32.5%(13/40)与45.0%(18/40)(P<0.05),研究组平均生存期25.5个月显著高于对照组17.2个月(P<0.05),1和3年生存率两组差异无统计学意义,P>0.05。结论:采用同步放化疗并序贯培养的CIK细胞与树突状细胞过继免疫治疗局部晚期非小细胞肺癌,临床疗效较好,可延缓患者生存期并提高生存质量。OBJECTIVE：To evaluate the effects of chemotherapy,radiotherapy and CIK cell and DC therapy for locally advanced non-small cell lung cancer（LANSCLC）.METHODS：Totally 85 patients with LANSCLC were randomized into study group（chemotherapy＋radiotherapy ＋ CIK＋ DC,n=45 and control group（chemotherapy＋radiotherapy,n=40.Study group adoptted NP scheme chemotherapy concurrent radiotherapy and sequential CIK cell and DC,and effect,toxicant,quality of living,immunological function and survival rate were observed.RESULTS： In the study group and the control group,the effective rate were 80.0%（36/45） and 57.5%（23/40）,respectively（P〈0.05）.Quality of living and immunological function of study group were higher than control group.The 2-year survival rates and the 1-year progressive free survival rates were 64.4%（29/45） vs 32.5%（13/40,P〈0.01）,75.6%（34/56） vs 45.0%（18/40,P〈0.05）.The mean survival time of study group（25.5 months） was significantly higher than that of control group（17.2 months,P〈0.05）.There was no significant difference of 1 and 3 year survival rates between two groups（P〉0.05）.CONCLUSION： Concurrent chemotherapy radiotherapy and sequential CIK cell can get better curative effect and improve immmunity function of the patients with LANSCLC.

关 键 词：癌 非小细胞肺/药物疗法 癌 非小细胞肺/放射疗法 过继免疫细胞 综合疗法 对比研究 

分 类 号：R734.2[医药卫生—肿瘤]